Liposomal AEEA Delivery for Scar Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hypertrophic scarring, particularly in burn patients, are inadequate, with limited effective options beyond surgical revision, and existing methods do not effectively address the pathological growth of scar tissue that restricts movement and causes morbidity.
Innovation Solution
A pharmaceutical liposome formulation containing N-(2-aminoethyl) ethanolamine (AEEA) and its active analogs, which are administered topically or ocularly to reduce scarring by altering matrix metabolism, specifically targeting hypertrophic scarring, keloid scarring, and other forms of scarring through the use of liposomes composed of various lipids and additional formulation components to enhance delivery and reduce dermatitis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high dose AEEA is used to treat scarring, then scarring reduction is improved, but dermatitis is caused
Solution Approach 1:
The patent changes the pH parameter of the formulation from acidic to a neutral or slightly alkaline range (pH 6.0-8.0), which reduces dermatitis while maintaining scarring reduction effectiveness. This parameter modification allows the active ingredient to remain effective without causing the harmful skin irritation associated with lower pH formulations
Solution Approach 2:
The patent introduces liposomes as a delivery vehicle that mediates between the active ingredient AEEA and the skin tissue. The liposomal encapsulation protects the skin from direct contact with high concentrations of AEEA that would cause dermatitis, while still delivering sufficient drug to achieve scarring reduction through controlled release
2Reliability
If surgical revision is used to treat hypertrophic scarring, then scarring appearance is improved, but treatment complexity and recovery time increase
Solution Approach 1:
The patent replaces the mechanical surgical intervention with a chemical/pharmaceutical approach. Instead of physically cutting and revising scar tissue through surgery, the treatment uses topically applied AEEA to chemically modify collagen production and matrix metabolism, thereby reducing scar tissue formation through biochemical mechanisms rather than mechanical removal
3Volume of stationary object
If existing collagen degrading compositions are used, then scar tissue size is reduced, but skin integrity and appearance may be compromised
Solution Approach 1:
The patent converts the potentially harmful effect of collagen degradation into a beneficial outcome by using AEEA to selectively modulate collagen metabolism. Rather than indiscriminately degrading all collagen (which could damage healthy skin), the treatment promotes selective breakdown of excessive scar collagen while preserving normal skin collagen through controlled biochemical pathways
Solution Approach 2:
The patent modifies the biochemical parameters of collagen metabolism through AEEA treatment, shifting the balance from excessive collagen production in scars to controlled collagen turnover. This parameter change affects collagen synthesis, degradation, and remodeling rates to reduce scar volume while maintaining skin integrity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation effectively reduces scarring by altering collagen production and matrix properties, providing a non-surgical treatment option that is effective without causing dermatitis, thereby improving the appearance and functionality of affected areas.
Implementation Method 1
a pharmaceutical liposome formulation thereof comprising: a N-(2-aminoethyl) ethanolamine (AEEA) and/or active analogs thereof in a liposome
Data Source
AI summary
The present invention includes pharmaceutical liposome formulation thereof comprising a N-(2-aminoethyl) ethanolamine (AEEA) and/or active analogs thereof in a liposome, wherein the N-(2-aminoethyl) ethanolamine (AEEA) and/or active analogs thereof are provided in an amount sufficient to treat or reduce scarring of the skin or eye.